All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Pirtobrutinib to be Compared with Ibrutinib in CLL/SLL Ongoing BRUIN CLL-314 Trial

October 13th 2023

The phase 3 BRUIN CLL-314 trial evaluating the selective noncovalent BTK inhibitor pirtobrutinib vs the potent covalent BTK inhibitor ibrutinib is currently enrolling patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received treatment with non-BTK inhibitor therapy.

Florida Cancer Specialists & Research Institute Clinicians Demonstrate Effectiveness of Positive Quality Interventions to Improve Care for Patients with Blood Disorders

October 12th 2023

The use of best practice guidance and resources developed through the Positive Quality Intervention initiative of NCODA improves the quality of care provided to patients with blood cancers and disorders.

Comprehensive Programs Are Needed to Address Therapeutic Needs in Sickle Cell Disease

October 12th 2023

Sickle cell disease, a chronic debilitating disorder, is characterized by ongoing hemolytic anemia, vaso-occlusive events, and progressive organ damage.

Ongoing Research Could Add to Atezolizumab/Bevacizumab Backbone in First-Line Treatment of Unresectable HCC

October 12th 2023

Daneng Li, MD, discusses the current options available for the frontline treatment of patients with unresectable HCC, factors to consider when selecting a treatment regimen for this patient population, how Child-Pugh B score and bleeding could affect these decisions, and ongoing research using the atezolizumab/bevacizumab backbone in novel combinations.

FDA Grants Fast Track Designation to SurVaxM in Newly Diagnosed Glioblastoma

October 12th 2023

The FDA has granted fast track designation to the investigational vaccine SurVaxM for the treatment of patients with newly diagnosed glioblastoma.

CYT-0851 Plus Capecitabine Demonstrates Efficacy in Advanced Ovarian Cancer

October 12th 2023

The combination of the novel MCT inhibitor CYT-0851 and capecitabine displayed clinical activity and a tolerable safety profile in patients with advanced platinum-resistant ovarian cancer.

Study Offers Way to Increase Immune Checkpoint Inhibitor Effectiveness in Patients With MTAP-Deleted Cancers

October 12th 2023

Loss of the “housekeeping” gene methylthioadenosine phosphorylase, or MTAP, is a common event in cancer.

First-Line UV1 Vaccine Plus Pembrolizumab Sustains OS in Unresectable or Metastatic Melanoma

October 12th 2023

First-line treatment with the universal cancer vaccine UV1 in combination with pembrolizumab sustained overall survival in patients with advanced unresectable or metastatic malignant melanoma, according to updated data from cohort 1 of the phase 1 UV1-103 trial.

Personalization Is Key to Successful Mentorship

October 12th 2023

Linda Hasunuma, PhD, highlights the importance of empathy and support as it relates to mentorship, as well as advice for establishing a successful fellowship program and communication strategies.

Strategies to Improve Manufacturing Time, Mitigate Toxicities of CAR T-Cell Therapy Remain a Focus in R/R LBCL

October 12th 2023

Hemant S. Murthy, MD, emphasizes the importance of an accelerated manufacturing process for CAR T-cell therapy, discusses the use of CAR T-cell therapy in older and frail patients, and highlights toxicity management strategies that have implemented and are under evaluation for patients receiving CAR T-cell therapy.

FDA Approves Encorafenib Plus Binimetinib for BRAF V600E+ Metastatic NSCLC

October 11th 2023

The FDA has approved encorafenib (Braftovi) plus binimetinib (Mektovi) for adult patients with metastatic non–small cell lung cancer harboring a BRAF V600E mutation, as detected by an FDA-approved test.

Let’s Talk About Post-Mastectomy Chest Numbness

October 11th 2023

Just as advances in surgical techniques have made it possible to treat breast cancer and offer numerous options for breast reconstruction, there is also a surgical advancement to address a functional impairment often unintentionally caused by mastectomy: chest numbness.

LSAM-PTX Demonstrates Disease Control, Safety in Locally Advanced Pancreatic Cancer

October 11th 2023

Treatment with intratumoral large surface area microparticle paclitaxel led to disease control and was well tolerated in patients with locally advanced pancreatic cancer.

FDA Awards Orphan Drug Designation to SLS009 in AML

October 11th 2023

The FDA has granted an orphan drug designation to SLS009 for the treatment of patients with acute myeloid leukemia.

Bexmarilimab Plus SOC Continues to Elicit Responses in R/R AML and HMA-Refractory MDS

October 11th 2023

The addition of bexmarilimab to standard-of-care azacitidine or azacitidine plus venetoclax continued to elicit responses in patients with relapsed or refractory acute myeloid leukemia and those with myelodysplastic syndrome who were refractory to hypomethylating agents.

Researcher to Present Study on Using MRI-guided Linear Accelerator System to Track Glioblastoma Progression

October 11th 2023

Kaylie Cullison, an award-winning researcher, MD/PhD student and mentee to Dr. Eric Mellon, will present data on true progression and pseudoprogression with the use of the MRI-linac machine.

First-Line TPST-1120 Plus Atezolizumab/Bevacizumab Improves Responses in Unresectable or Metastatic HCC

October 11th 2023

The addition of TPST-1120 to the combination of atezolizumab and bevacizumab led to improved responses vs atezolizumab plus bevacizumab alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma.

ACCC Releases Trending Now in Cancer Care

October 11th 2023

The Association of Community Cancer Centers today released its annual Trending Now in Cancer Care report, including actionable strategies in 8 key areas.

Understanding the Impact of Population Genetics on Cancer Treatment

October 11th 2023

Population genetics integrates genetics and large-scale electronic health record data to identify meaningful biomarkers of treatment consequences and develop algorithmic models to support clinical decision-making.

Tazemetostat Addition Aims to Bolster Efficacy of Lenalidomide Plus Rituximab in R/R Follicular Lymphoma

October 11th 2023

Although relapsed/refractory follicular lymphoma remains a difficult- to-treat disease, the emergence of anti-CD20 monoclonal antibodies in recent years has signaled progress, including the 2019 FDA approval of rituximab plus lenalidomide.